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Mucopolysaccharidoses (MPS) are inherited metabolic disorders, caused by mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Due to their impaired degradation, GAGs accumulate in cells of patients, which results in dysfunction of tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Depending on the kind of deficient enzyme, 11 types and subtypes of MPS are currently recognized. Although enzyme replacement therapy has been developed for 3 types of MPS (types I, II and VI), this treatment was found to be effective only in management of somatic symptoms. Since all MPS types except IVA, IVB and VI are characterized by various problems with functioning of the central nervous system (CNS), a search for effective treatment of this system is highly desirable. Recent discoveries suggested that substrate reduction therapy may be an efficient method for treatment of MPS patients, including their CNS. In this review, different variants of this therapy will be discussed in the light of recently published reports. 











Treatment of neurodegenerative diseases is a challenge for current pharmacology and biotechnology [1-5]. The complicated structure of brain and problems with delivery of certain drugs, especially those consisting of large biomolecules, through the blood-brain-barrier (BBB) make the problem especially difficult. On the other hand, neurodegenerative diseases are relatively frequent and often very severe, with high morbidity and mortality, thus, being considered as a major medical and social problem. 
Some neurodegenerative diseases are inherited, which adds another difficulty to their treatment as little, if any, prophylactic procedures can be used to prevent their development. Although gene therapy might be a potential effective treatment for such disorders [6], the problem is that this kind of therapy is still under development and despite many tests on animal models and still ongoing clinical trials, there is no gene therapy procedure officially approved as a treatment for neurodegenerative disease. Among inherited neurodegenerative disorders, there is a large group of lysosomal storage diseases (LSD), caused by dysfunction of one or more lysosomal enzymes, characterized by neuronopathic symptoms [7]. Since molecular mechanisms of LSD are rather well understood (relative to many other diseases of this nature), and as they were among the first genetic diseases for which effective – at least to some extent - treatment became possible, these disorders may be considered as models in inherited metabolic diseases, including its neurodegenerative component. 




Mucopolysaccharidoses (MPS) belong to LSD and are caused by mutations in genes coding for enzymes involved in degradation of glycosaminoglycans (GAGs) (formerly called mucopolysaccharides) [9]. Impaired hydrolysis of GAGs leads to continuous accumulation  and storage of these compounds in cells of patients, which result in a progressive damage of the affected tissues, including the heart, respiratory system, bones, joints and CNS (in most MPS types and subtypes). MPS are usually fatal diseases, with average expected life span of one or two decades, though patients with milder forms can survive into adulthood [9].
There are 11 known types and subtypes of MPS, depending on the nature of lacking or defective enzyme and the kind(s) of stored GAG(s). Among those 11 forms of MPS, neurodegeneration occurs in most of them, with only three (types IVA, IVB and VI) definitely free of neuronopathy (Table 1). Until now, only one patient suffering from MPS IX has been described [10], and although no neurological symptoms were found, this case in non-conclusive on whether MPS IX is a neuronopathic or non-neuronopathic disease. 
A characteristic feature of each MPS type is a huge variability in the spectrum and severity of symptoms [9]. Prediction of severity and clinical progression of MPS is difficult, or even impossible, despite biochemical and genetic data may be available [11]. Recent studies suggested that considering two or more parameters may give significantly better results than attempting to make conclusion based on a single biomarker [12]. Nevertheless, although the variability of MPS makes serious problems for clinicians who must decide about choosing potentially optimal management and symptomatic treatment of patients, this feature provides a tool for studying molecular mechanisms of the disease and developing novel therapeutic strategies [11]. Thus, MPS can be considered as good models in biotechnological studies on development of new pharmaceuticals for treatment of neurodegenerative genetic diseases. 
Currently, bone marrow or hematopoietic stem cells’ transplantations (with still unproved efficacy) and ERT are the only officially approved treatments of MPS. ERT is used in a clinical practice for only 3 MPS types, namely MPS I, II and VI [8, 13]. As mentioned above, neurological symptoms developed due to GAG accumulation in CNS cannot be managed by ERT owing to an inefficient delivery of proteins through BBB [13]. Although gene therapy is a hope for MPS patients, it still remains a treatment under development rather than a real therapy [14]. Therefore, there is still a need for alternative therapies, which could be helpful for patients suffering from MPS, especially from neuronopathic forms. Moreover, since advances in biochemistry and genetics have resulted in understanding molecular bases of MPS, with subsequent development of specific treatment regimens for some of these diseases (ERT for MPS I, II and VI), it is believed that experience gained in MPS by the development, evaluation and integration of treatment regimens into healthcare may be instructive for other genetic disorders [15].

DEVELOPMENT OF SUBSTRATE REDUCTION THERAPIES FOR MUCOPOLYSACCHARIDOSES

	Since neither bone marrow transplantation nor enzyme replacement therapy can be effective in treatment of neurological symptoms of MPS, especially severe ones, development of alternative therapies became necessary, especially for MPS types in which neuronopathic forms predominate, like Sanfilippo disease (Table 1). Several approaches has been tested, with some achieving the phase of clinical trials, however, such trials with glucosamine (which was expected to alleviate symptoms of MPS III due to its similarity to the terminal carbohydrate moiety present in partially degraded heparan sulfate molecules that are stored in Sanfilippo cells) and miglustat (which should inhibit synthesis of gangliosides, compounds that are secondary products of GAG storage [16]) were not successful. Therefore, there is still a need for effective method to treat neuronopathic forms of MPS (for reviews see [17-19]). 




	Rhodamine B ([9-(2-carboxyphenyl)-6-diethylamino-3-xanthenylidene]-diethylammonium chloride) is a synthetic chemical, commonly used in biological studies as a staining fluorescent dye. It has been demonstrated that this compound reduced GAG synthesis in cultures of MPS IIIA and MPS VI cells [21]. Moreover, addition of rhodamine B into cultures of MPS IIIA and MPS VI fibroblasts resulted in a significant decrease in lysosomal storage of GAGs [21]. MPS IIIA mice were treated with rhodamine B at the dose of 1 mg/ml, and GAG levels were reduced relative to untreated animals. Particularly, liver size, total GAG content, and lysosomal GAG was reduced as was urinary GAG excretion. It is of special interest that lysosomal GAG content in the brain was also significantly reduced by this treatment, which was perhaps possible because of a potential of rhodamine B to cross BBB [21]. These results demonstrated that SRT is even more efficient in treatment of MPS symptoms that it was expected earlier. Namely, it was supposed that inhibition of the substrate production might slow down or, at best, halt the progression of the disease, rather than reverse the symptoms.
	Of outstanding importance are studies on MPS IIIA mice treated with rhodamine B, in which behavioral tests were performed, and spatial learning and memory were assessed [22]. Contrary to control MPS IIIA mice, the rhodamine B-treated MPS IIIA mice improved performance towards normal animals [22]. These results provided the first evidence for beneficial effect on CNS function in an MPS disorder due to the use of SRT.
 	Although experiments with rhodamine B provided important support for efficacy of SRT in MPS, there are serious problems which preclude the use of this compound as a drug for humans. Firstly, rhodamine B appears to be a non-specific inhibitor of GAG synthesis [21], and in fact, a mechanism for its action is unknown (Fig. 1). Secondly, and perhaps more importantly, rhodamine B is supposed to be toxic for humans [21]. It is considered harmful to humans if swallowed, and may cause irritation of skin, eyes and respiratory tract (see, for example: http://www.jtbaker.com/msds/englishhtml/r5400.htm). Therefore, despite very promising results of studies on cell cultures and mice, it is unlikely that rhodamine B can be used as a drug for MPS treatment.

Gene expression-targeted isoflavone therapy

Simultaneously with studies on rhodamine B, research on inhibition of GAG synthesis by another compound, genistein (5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one) was conducted. Genistein is a natural isoflavone occurring in many plants, and known to possess various biological activities, ranging from phytoestrogenic to antioxidative actions [23, 24]. When added to cultures of fibroblast of MPS I, MPS II, MPS IIIA and MPS IIIB patients, this compound, at concentrations between 10 and 30 M, inhibited GAG synthesis and reduced lysosomal GAG storage [25]. 
Contrary to rhodamine B, it was possible to learn about the mechanism of genistein-mediated inhibition of GAG synthesis. An excess of epidermal growth factor (EGF) abolished genistein-mediated impairment of GAG synthesis in cultured fibroblasts, while increased concentrations of genistein partially restored this negative regulation [26]. Moreover, genistein affected EGF receptor-catalyzed phosphorylation efficiency [26]. EGF is a ligand, whose binding by its specific receptor (EGF receptor) triggers a signal transduction pathway resulting in activation of expression of certain genes [27], apparently including genes coding for enzymes required for GAG synthesis. Therefore, the potential therapy based on the use of genistein (an isoflavone) as an inhibitor of the EGF-mediated signal transduction pathway, has been named ‘gene expression-targeted isoflavone therapy’ (GET IT) [25, 26]. In this light, effects of the action of genistein on MPS cells are compatible with results of recent studies, indicating that efficiency of GAG synthesis may significantly influence severity of MPS diseases [28]. The mode of genistein action as an inhibitor of GAG synthesis is summarized in Fig. 1.
Similarly to rhodamin B, genistein caused a marked improvement in treated mice suffering from Sanfilippo disease (in these experiments, MPS IIIB mice were used) [29]. Importantly, no adverse effects related to genistein administration were observed, despite the doses used were from 5 mg/kg to as high as 160 mg/kg.
Efficacy in pre-clinical studies and a lack of toxicity of genistein, confirmed by results on the MPS IIIB mouse model [29] and deduced on the basis of a large body of previously published data [30], encouraged researchers and clinicians to perform a pilot clinical study on the use of GET IT in treatment of patients suffering from Sanfilippo disease. In this open-label study, 10 patients diagnosed as MPS IIIA or MPS IIIB were treated for 12 months with a genistein-rich soy isoflavone extract  at the dose corresponding to 5 mg genistein per 1 kg of body weight daily [31]. This treatment, in which no adverse effects were noted, resulted in a statistically significant improvement in all tested parameters in this group of patients [31]. Namely, urinary GAG levels were reduced, hair morphology (suggested to be a useful parameter in monitoring efficacy of treatment of patients suffering from various MPS types [32-34]) improved, and patients got higher scores in the psychological test by which cognitive functions could be assessed [31]. 
The improvement in brain functions (assessed by estimation of cognitive abilities) of MPS III patients after treatment with GET IT appears to be of special importance, considering the nature of symptoms of Sanfilippo disease. In fact, the paper describing these results [31]  was the first report demonstrating an improvement of MPS III patients after pharmacological treatment. Moreover, it indicated that neurological functions, already lost due to neurodegeneration in the course of a genetic disease, can be restored (at least partially) after pharmacological treatment.
 It is interesting to ask whether action of genistein as an inhibitor of the EGF-mediated signal transduction pathway is the only mechanism causing efficacy of GET IT? Beside storage of GAGs in cell lysosomes and secondary storage of gangliosides (mentioned above), oxidative stress, inflammation, cytotoxicity and apoptosis were postulated to be involved in the mechanism of neurodegeneration in MPS [35-37]. In addition, accumulation of hyperphosphorylated tau protein (P-tau), which forms aggregates characteristic for Alzheimer disease, has been detected in brains of MPS IIIB mice [38]. Considering these facts, it is of interest to note that genistein may be effective in prevention of the devastating processes in brain or amelioration of the function of affected brain. Namely, genistein could attenuate oxidative stress in brain [39], and revealed neuroprotective effect against beta amyloid-induced neurotoxicity [40, 41]. Moreover, genistein inhibited apoptosis in primary neuronal cell cultures [42] and prevented  Alzheimer's disease-associated inflammation [43]. General neuroprotective effects of genistein were also described [44]. Therefore, one might speculate that various neuroprotective activities of this isoflavone may contribute to the mechanism of efficacy of GET IT. It was also demonstrated that genistein can enhance expression of synaptophysin [45]. This can suggest a genistein-mediated stimulation of synapse formation, which might serve as a partial explanation of the phenomenon of gaining cognitive functions by MPS III patients subjected to GET IT [31] that are otherwise continuously deteriorating.     
 
RNAi-mediated silencing of genes involved in GAG synthesis

RNA interference (RNAi) is a process regulating gene expression by sequence-directed silencing of translation due to degradation of specific mRNA or translation inhibition [46]. Since impairment of GAG synthesis appeared effective in storage reduction in MPS cells (see preceding sections), the idea appeared that silencing of specific genes coding for enzymes involved in GAG production may be a precise method for substrate reduction therapy for MPS. Therefore, two research groups developed procedures to impair expression of such genes, though various genes were chosen and different techniques were employed.
One group has used shRNA molecules specific to EXTL2 and EXTL3 genes [47]. A significantly reduced expression of endogenous target genes was observed, as was a decreased GAG synthesis. Moreover, lysosomal GAG levels were reduced in MPS I and MPS IIIA fibroblasts treated with EXTL2- and EXTL3-specific shRNAs [47].
The second group employed siRNA oligonucleotides to reduce mRNA levels of four genes, XYLT1, XYLT2, GALTI and GALTII, whose products are required for GAG synthesis [48]. Following transfection of MPS IIIA fibroblasts, a significant decrease in levels of corresponding transcripts was observed. This was accompanied by a decrease in levels of proteins encoded by these genes. Efficiency of GAG production in the fibroblasts was considerably reduced after treatment of these cells with siRNA [48].
	The results reported by both groups [47, 48] indicated that impairment of expression of particular genes coding for enzymes required for GAG synthesis may be effective in reduction of lysosomal storage in various MPS types. Moreover, they support the conclusion that SRT can be a method suitable for treatment of patients suffering from MPS. Although different genes were silenced in experiments performed by certain groups (Fig. 2), and thus, GAG synthesis was inhibited at various stages of the synthesis pathway, efficiency of this inhibition was comparable in all cases, and corresponded to efficiency of reduction of the storage material [47, 48]. 
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Table 1. Mucopolysaccharidoses (MPS), stored GAGs, deficient enzymes and neurological symptoms 

MPS type (syndrome name)	Main GAGs stored in cellsa	Deficient enzyme	Neurological symptoms
MPS I (Hurler disease - MPS I-H, Scheie disease – MPS I-S, Hurler-Scheie disease – MPS I-H/S) 	DS, HS	-L-iduronidase	Severe (in the MPS I-H clinical subtype), very mild to mild (in MPS I-H/S) or none (in MPS I-S) 
MPS II (Hunter disease)	DS, HS	Iduronate sulfatase	Severe or mild (rarely none)
MPS IIIA (Sanfilippo disease subtype A)	HS	heparan N-sulfatase	Severe
MPS IIIB (Sanfilippo disease subtype B)	HS	-N-acetyl-glucosaminidase	Severe
MPS IIIC (Sanfilippo disease subtype C)	HS	acetyl-CoA:-glycosaminide acetyltransferase	Severe
MPS IIID (Sanfilippo disease subtype D)	HS	N-acetylglucosamine 6-sulfatase	Severe
MPS IVA (Morquio disease subtype A)	KS	N-acetylgalactos-aminide 6-sulfatase	None
MPS IVB (Morquio disease subtype B)	KS	-galactosidase	None
MPS VI (Maroteaux-Lamy disease)	DS	N-acetylgalactos-amine 4-sulfatase	None
MPS VII (Sly disease)	DS, HS	-glucuronidase	Severe or mild (rarely none)
MPS IX	Hyaluronan	Hyaluronidase	Noneb

a Abbreviations: DS – dermatan sulfate, HS – heparan sulfate, KS – keratan sulfate  





Figure 1. A scheme for expression of genes coding for enzymes involved in GAG synthesis, with stages inhibited by various methods of SRT indicated by blunt-ended lines. Mechanism of the rhodamine B-mediated inhibition is not known. Competitive inhibition of enzymes by monosaccharide analogs (dashed line) appears unlikely to be used as a therapeutic procedure due to potential side effects caused by blocking of other biochemical pathways, in which these monosaccharides are involved. 

Figure 2. A scheme for syntheses of heparan sulfate and dermatan sulfate (two kinds of GAGs, stored in most MPS types, except MPS IV and IX) with marked enzymes catalyzing particular reactions. Monosaccharides used for GAG synthesis are indicated by symbols explained in the figure. Silencing of expression of particular genes, coding for corresponding enzymes, by either siRNA (according to Dziedzic et al. [48]) or shRNA (according to Kaidonis et al. [47]), is indicated.
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